| Microsatellite instability: diagnosis, heterogeneity, discordance, and clinical impact in colorectal cancer C Evrard, G Tachon, V Randrian, L Karayan-Tapon, D Tougeron Cancers 11 (10), 1567, 2019 | 155 | 2019 |
| Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell … J Guigay, A Aupérin, J Fayette, E Saada-Bouzid, C Lafond, M Taberna, ... The Lancet Oncology 22 (4), 463-475, 2021 | 129 | 2021 |
| Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study D Tougeron, B Sueur, A Zaanan, C de la Fouchardiére, D Sefrioui, ... International Journal of Cancer 147 (1), 285-296, 2020 | 62 | 2020 |
| Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor L de Mestier, T Walter, C Evrard, P de Boissieu, O Hentic, J Cros, ... Neuroendocrinology 110 (1-2), 83-91, 2020 | 54 | 2020 |
| Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer AGDA De Salins, G Tachon, R Cohen, L Karayan-Tapon, A Junca, ... ESMO open 6 (3), 100120, 2021 | 51 | 2021 |
| Comparison of temozolomide-capecitabine to 5-fluorouracile-dacarbazine in 247 patients with advanced digestive neuroendocrine tumors using propensity score analyses L de Mestier, T Walter, H Brixi, C Evrard, JL Legoux, P de Boissieu, ... Neuroendocrinology 108 (4), 343-353, 2019 | 48 | 2019 |
| Microsatellite instability in colorectal cancers: carcinogenesis, neo-antigens, immuno-resistance and emerging therapies V Randrian, C Evrard, D Tougeron Cancers 13 (12), 3063, 2021 | 42 | 2021 |
| Characterization and performance of the Apollon short-focal-area facility following its commissioning at 1 PW level K Burdonov, A Fazzini, V Lelasseux, J Albrecht, P Antici, Y Ayoul, ... Matter and Radiation at Extremes 6 (6), 2021 | 36 | 2021 |
| Predictive and prognostic value of microsatellite instability in gynecologic cancer (endometrial and ovarian) C Evrard, J Alexandre Cancers 13 (10), 2434, 2021 | 29 | 2021 |
| Detection of colorectal cancer and advanced adenoma by liquid biopsy (decalib study): The ddpcr challenge A Junca, G Tachon, C Evrard, C Villalva, E Frouin, L Karayan-Tapon, ... Cancers 12 (6), 1482, 2020 | 21 | 2020 |
| Targeted RNA‐sequencing assays: a step forward compared to FISH and IHC techniques? G Tachon, U Cortes, S Richard, S Martin, S Milin, C Evrard, C Lamour, ... Cancer medicine 8 (18), 7556-7566, 2019 | 20 | 2019 |
| Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: a French comprehensive multicentre ambispective observational cohort … M Brugel, L Letrillart, C Evrard, A Thierry, D Tougeron, M El Amrani, ... European Journal of Cancer 166, 8-20, 2022 | 19 | 2022 |
| PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI+ Durvalumab±Tremelimumab in second-line of patients with advanced gastric cancer C Evrard, C Louvet, FEL Hajbi, FDI Fiore, KLE Malicot, T Aparicio, ... Digestive and Liver Disease 53 (4), 420-426, 2021 | 14 | 2021 |
| GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with … J Guigay, A Aupérin, J Fayette, E Saada-Bouzid, C Lafond, M Taberna, ... Lancet Oncol 22 (4), 463-475, 2021 | 12 | 2021 |
| Heterogeneity of mismatch repair status and microsatellite instability between primary tumour and metastasis and its implications for immunotherapy in colorectal cancers C Evrard, S Messina, D Sefrioui, É Frouin, ML Auriault, R Chautard, ... International Journal of Molecular Sciences 23 (8), 4427, 2022 | 10 | 2022 |
| Efficacy of anti-EGFR in microsatellite instability metastatic colorectal cancer depending on sporadic or familial origin A Zaanan, J Henriques, R Cohen, D Sefrioui, C Evrard, ... JNCI: Journal of the National Cancer Institute 113 (4), 496-500, 2021 | 5 | 2021 |
| Safety of FOLFIRI+ Durvalumab+/− Tremelimumab in Second Line of Patients with Advanced Gastric Cancer: A Safety Run-In from the Randomized Phase II Study DURIGAST PRODIGE 59 C Evrard, T Aparicio, E Soularue, K Le Malicot, J Desramé, D Botsen, ... Biomedicines 10 (5), 1211, 2022 | 4 | 2022 |
| Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study C Evrard, P Ingrand, T Rochelle, M Martel, G Tachon, N Flores, ... Digestive and Liver Disease 55 (11), 1562-1572, 2023 | 3 | 2023 |
| Survival outcomes, prognostic factors, and effect of adjuvant radiotherapy and prophylactic neck dissection in salivary acinic cell carcinoma: A prospective multicenter REFCOR … F Chatelet, FR Ferrand, S Atallah, J Thariat, F Mouawad, N Fakhry, ... European Journal of Cancer 185, 11-27, 2023 | 2 | 2023 |
| An Innovative and Accurate Next-Generation Sequencing–Based Microsatellite Instability Detection Method for Colorectal and Endometrial Tumors C Evrard, U Cortes, B Ndiaye, J Bonnemort, M Martel, R Aguillon, ... Laboratory Investigation 104 (2), 100297, 2024 | 1 | 2024 |
